Brief: Transcenta Says Collaboration With Agilent Technologies To Develop A Claudin18.2 Companion Diagnostic
09/04/2024 02:21
April 9 (Reuters) - Transcenta Holding Limited
6628.HK :
* COLLABORATION WITH AGILENT TECHNOLOGIES TO DEVELOP A
CLAUDIN18.2
COMPANION DIAGNOSTIC
* COLLABORATION TO SUPPORT OSEMITAMAB (TST001) GLOBAL PHASE
III
TRIAL
Further company coverage: 6628.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcenta Holding
See all newsBrief: Transcenta Says Global Phase III Trial Of Osemitamab Approved By FDA, China, Korea Regulators
Brief: Transcenta Holding Says Unit To Sell CDMO Assets For RMB190.0 Million
Brief: Transcenta Holding To Revert Assets To Lilly For $4 Million Cash
Brief: Transcenta Therapeutics Appoints Dr. Christopher Hwang As Head Of Global Partnerships For Hicb Platform
Brief: Transcenta Announces Collaboration And Non-Exclusive Licensing Agreement With Eirgenix Inc.